BB Biotech AG : The holding ends the year on a positive note
>A positive Q4 but not enough to improve the 2023 performance - This morning, BB Biotech published its Q4 2023 results. The share price gained 7.1% in € and 3.4% in CHF over the quarter. Over the period, NAV of the portfolio gained +5% in CHF and 14.2% in $ whereas the benchmark NBI (Nasdaq Biotechnology Index) gained around 3% over the last quarter of the year. This results in a net gain of CHF 109m over the period (vs a loss of CHF 35m in Q4 2022). However, the...Co.'s principal activity is to invest in biotechnology companies globally. The investments are held through its wholly-owned subsidiaries: Biotech Focus N.V., Biotech Invest N.V., Biotech Target N.V., and Biotech Growth N.V., all of which are located in Curacao. Co. acquires holdings in companies in the biotechnology growth market. The focus of the holdings is on quoted companies that are concentrating on the development and marketing of innovative medicines. For the selection of holdings, Co. relies on fundamental analysis by physicians and molecular biologists.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.